PMID- 31790382
OWN - NLM
STAT- MEDLINE
DCOM- 20200513
LR  - 20220701
IS  - 1643-3750 (Electronic)
IS  - 1234-1010 (Print)
IS  - 1234-1010 (Linking)
VI  - 25
DP  - 2019 Dec 2
TI  - Comparison of Regorafenib, Fruquintinib, and TAS-102 in Previously Treated 
      Patients with Metastatic Colorectal Cancer: A Systematic Review and Network 
      Meta-Analysis of Five Clinical Trials.
PG  - 9179-9191
LID - 10.12659/MSM.918411 [doi]
AB  - BACKGROUND This study aimed to conduct a systematic review of the literature to 
      identify key randomized controlled clinical trials (RCTs), followed by network 
      meta-analysis, to compare the efficacy and safety profiles of regorafenib, 
      fruquintinib, and TAS-102 in previously treated patients with metastatic 
      colorectal carcinoma (mCRC). MATERIAL AND METHODS Systematic literature review 
      was performed using the Medline, Embase, and Cochrane library online databases to 
      identify published randomized controlled trials (RCTs). Hazard ratios (HRs) for 
      progression-free survival (PFS), overall survival (OS), and the odds ratios (ORs) 
      for the objective response rate (ORR), disease control rate (DCR), adverse events 
      (AEs), serious adverse events (SAEs), and fatal adverse events (FAEs) were 
      compared indirectly using network meta-analysis based on a random-effects model. 
      RESULTS Five RCTs that included 2,604 patients fulfilled the eligibility criteria 
      and were analyzed. Indirect comparisons showed that fruquintinib was associated 
      with significant superiority for PFS (HR, 0.57; 95% CI, 0.34-0.95) and DCR (OR, 
      1.80; 95% CI, 1.08-3.01) when compared with TAS-102 in patients with mCRC. 
      However, there was no significant difference between OS or ORR between 
      regorafenib, fruquintinib, and TAS-102. Fruquintinib was associated with a 
      significantly higher risk of SAEs when compared with TAS-102 or regorafenib. 
      There was no significant difference in the risk of AEs or FAEs following indirect 
      comparison between fruquintinib, regorafenib, and TAS-102. CONCLUSIONS The 
      findings from network meta-analysis showed that fruquintinib was associated with 
      significant superiority for PFS and DCR compared with TAS-102, but fruquintinib 
      was associated with significantly increased risk for SAEs compared with 
      regorafenib and TAS-102.
FAU - Chen, Jianxin
AU  - Chen J
AD  - Department of Medical Oncology, Quzhou People's Hospital, Quzhou, Zhejiang, China 
      (mainland).
FAU - Wang, Junhui
AU  - Wang J
AD  - Department of Radiation Oncology, Quzhou People's Hospital, Quzhou, Zhejiang, 
      China (mainland).
FAU - Lin, Hai
AU  - Lin H
AD  - Department of Gastroenterology, Quzhou People's Hospital, Quzhou, Zhejiang, China 
      (mainland).
FAU - Peng, Yonghai
AU  - Peng Y
AD  - Department of Oncology, Fuzhou General Hospital, Fuzhou, Fujian, China 
      (mainland).
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20191202
PL  - United States
TA  - Med Sci Monit
JT  - Medical science monitor : international medical journal of experimental and 
      clinical research
JID - 9609063
RN  - 0 (Benzofurans)
RN  - 0 (Drug Combinations)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Pyridines)
RN  - 0 (Pyrrolidines)
RN  - 0 (Quinazolines)
RN  - 0 (trifluridine tipiracil drug combination)
RN  - 24T2A1DOYB (regorafenib)
RN  - 49DXG3M5ZW (HMPL-013)
RN  - 56HH86ZVCT (Uracil)
RN  - QR26YLT7LT (Thymine)
RN  - RMW9V5RW38 (Trifluridine)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Benzofurans/pharmacology/*therapeutic use
MH  - Colonic Neoplasms/drug therapy
MH  - Colorectal Neoplasms/*drug therapy/pathology
MH  - Disease-Free Survival
MH  - Drug Combinations
MH  - Humans
MH  - Network Meta-Analysis
MH  - Phenylurea Compounds/pharmacology/*therapeutic use
MH  - Pyridines/pharmacology/*therapeutic use
MH  - Pyrrolidines/pharmacology/*therapeutic use
MH  - Quinazolines/pharmacology/*therapeutic use
MH  - Rectal Neoplasms/drug therapy
MH  - Thymine
MH  - Trifluridine/pharmacology/*therapeutic use
MH  - Uracil/*analogs & derivatives/pharmacology/therapeutic use
PMC - PMC6909918
COIS- Conflict of interest None.
EDAT- 2019/12/04 06:00
MHDA- 2020/05/14 06:00
PMCR- 2019/12/02
CRDT- 2019/12/03 06:00
PHST- 2019/12/03 06:00 [entrez]
PHST- 2019/12/04 06:00 [pubmed]
PHST- 2020/05/14 06:00 [medline]
PHST- 2019/12/02 00:00 [pmc-release]
AID - 918411 [pii]
AID - 10.12659/MSM.918411 [doi]
PST - epublish
SO  - Med Sci Monit. 2019 Dec 2;25:9179-9191. doi: 10.12659/MSM.918411.